Literature DB >> 9457427

The lipids of Pneumocystis carinii.

E S Kaneshiro1.   

Abstract

Information about a number of Pneumocystis carinii lipids obtained by the analyses of organisms isolated and purified from infected lungs of corticosteroid-immunosuppressed rats has been reported in recent years. Of the common opportunistic protists associated with AIDS (Cryptosporidium, Toxoplasma, and the microsporidia), more is currently known about the lipids of P. carinii than the others. Lipids that are synthesized by the organism but not by humans are attractive targets for drug development. Thus, the elucidation of delta 7C-24-alykylated sterol and cis-9,10-epoxystearic acid biosyntheses in P. carinii is currently being examined in detail, since these have been identified as P. carinii-specific lipids. The development of low-toxicity drugs that prevent sterol C-24 alkylation and the specific inhibition of the lipoxygenase that forms cis-9,10-epoxystearic acid might prove fruitful. Although humans can synthesize coenzyme Q10, the anti-P. carinii activity and low toxicity of ubiquinone analogs such as atovaquone suggest that the electron transport chain in the pathogen may differ importantly from that in the host. Although resistance to atovaquone has been observed, development of other naphthoquinone drugs would provide a broader armamentarium of drugs to treat patients with P. carinii pneumonia. Studies of bronchoalveolar lavage fluid and of infected lungs have demonstrated that the infection causes a number of chemical abnormalities. Bronchoalveolar lavage fluid obtained after the removal of lung cellular material and the organisms has been shown to contain larger amounts of surfactant proteins and smaller amounts of phospholipids than do comparable samples from P. carinii-free lungs. Increased phospholipase activity, inhibition of surfactant secretion by type II cells, and uptake and catabolism of lipids by the pathogen may explain this phenomenon related to P. carinii pneumonia. Although not yet thoroughly examined, initial studies on the uptake and metabolism of lipids by P. carinii suggest that the organism relies heavily on exogenous lipid nutrients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457427      PMCID: PMC121374          DOI: 10.1128/CMR.11.1.27

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  90 in total

1.  Subpopulations of Pneumocystis carinii separated by a Percoll gradient.

Authors:  K Chin; S Merali; M M Shaw; M S Bartlett; A B Clarkson
Journal:  J Eukaryot Microbiol       Date:  1996 Sep-Oct       Impact factor: 3.346

2.  Refined structure of the lipophosphoglycan of Leishmania donovani.

Authors:  J R Thomas; M J McConville; J E Thomas-Oates; S W Homans; M A Ferguson; P A Gorin; K D Greis; S J Turco
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

3.  Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.

Authors:  M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  Control of fungal sterol C-24 transalkylation: importance to developmental regulation.

Authors:  W D Nes; P K Hanners; E J Parish
Journal:  Biochem Biophys Res Commun       Date:  1986-09-14       Impact factor: 3.575

5.  Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.

Authors:  C Contini; M Manganaro; R Romani; S Tzantzoglou; I Poggesi; V Vullo; S Delia; C De Simone
Journal:  J Antimicrob Chemother       Date:  1994-11       Impact factor: 5.790

6.  Multiple functions for sterols in Saccharomyces cerevisiae.

Authors:  R J Rodriguez; C Low; C D Bottema; L W Parks
Journal:  Biochim Biophys Acta       Date:  1985-12-04

7.  Evidence for the existence of ganglioside molecules on Pneumocystis carinii from human lungs.

Authors:  M Sorice; L Lenti; R Misasi; C Contini; L Cignarella; T Griggi; V Vullo; C Masala
Journal:  Parasitology       Date:  1992-08       Impact factor: 3.234

8.  Fetal bovine serum induces changes in fatty acid composition of Trypanosoma cruzi phosphoinositides.

Authors:  G Racagni; M G de Lema; G Hernández; E E Machado-Domenech
Journal:  Can J Microbiol       Date:  1995-10       Impact factor: 2.419

9.  Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.

Authors:  A G Hoffman; M G Lawrence; F P Ognibene; A F Suffredini; G Y Lipschik; J A Kovacs; H Masur; J H Shelhamer
Journal:  Chest       Date:  1992-12       Impact factor: 9.410

10.  Pneumocystis carinii is not universally transmissible between mammalian species.

Authors:  F Gigliotti; A G Harmsen; C G Haidaris; P J Haidaris
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

View more
  5 in total

1.  Heterogeneity of Pneumocystis sterol profiles of samples from different sites in the same pair of lungs suggests coinfection by distinct organism populations.

Authors:  Z Amit; E S Kaneshiro
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Sterols of Pneumocystis carinii hominis organisms isolated from human lungs.

Authors:  E S Kaneshiro; Z Amit; J Chandra; R P Baughman; C Contini; B Lundgren
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  C27 to C32 sterols found in Pneumocystis, an opportunistic pathogen of immunocompromised mammals.

Authors:  E S Kaneshiro; M A Wyder
Journal:  Lipids       Date:  2000-03       Impact factor: 1.880

4.  Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of pneumocystis carinii f. sp. carinii.

Authors:  E S Kaneshiro; M S Collins; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 5.  Non-Cellular Layers of the Respiratory Tract: Protection against Pathogens and Target for Drug Delivery.

Authors:  Eleonore Fröhlich
Journal:  Pharmaceutics       Date:  2022-05-05       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.